No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
It was understood the company is planning to axe around 50 roles at its main R&D hub in Stevenage, Hertfordshire.
A spokesperson for the drugs giant said in a statement: "GSK R&D investment has risen by almost 90% over recent years (to 6.4bn in 2024) and we expect it to increase further as we focus on delivering our pipeline of new medicines with multi-blockbuster potential before 2031.
"As we increase investment, we're focused on allocating resources to these priorities and making sure we have the right people in the right teams. Alongside this, we're investing in technology to maximise our scientific capabilities and drive productivity, and in our key R&D sites over the next five years to accelerate drug discovery and research."
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.